Baird Financial Group Inc. Buys 64,687 Shares of Ventas, Inc. $VTR

Baird Financial Group Inc. increased its stake in Ventas, Inc. (NYSE:VTR) by 39.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 227,174 shares of the real estate investment trust’s stock after purchasing an additional 64,687 shares during the quarter. Baird Financial Group Inc.’s holdings in Ventas were worth $20,173,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Dynamic Wealth Strategies LLC acquired a new position in shares of Ventas during the first quarter worth approximately $25,000. Wiser Advisor Group LLC bought a new position in shares of Ventas during the 3rd quarter worth about $27,000. Silvant Capital Management LLC acquired a new position in shares of Ventas during the second quarter valued at about $28,000. Meeder Asset Management Inc. acquired a new position in shares of Ventas during the second quarter valued at about $30,000. Finally, IFC & Insurance Marketing Inc. bought a new stake in shares of Ventas in the fourth quarter valued at about $30,000. Institutional investors own 94.18% of the company’s stock.

Ventas Stock Performance

NYSE:VTR opened at $90.10 on Friday. Ventas, Inc. has a 1 year low of $66.54 and a 1 year high of $101.60. The firm has a 50 day moving average of $92.89 and a 200-day moving average of $87.97. The company has a current ratio of 0.44, a quick ratio of 0.44 and a debt-to-equity ratio of 0.86. The stock has a market capitalization of $46.22 billion, a P/E ratio of 166.85, a price-to-earnings-growth ratio of 3.53 and a beta of 0.70.

Ventas (NYSE:VTR) last posted its quarterly earnings data on Wednesday, July 29th. The real estate investment trust reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.01. The company had revenue of $1.73 billion for the quarter, compared to analyst estimates of $1.68 billion. Ventas had a return on equity of 1.99% and a net margin of 4.08%.The business’s revenue was up 21.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.87 earnings per share. As a group, sell-side analysts anticipate that Ventas, Inc. will post 3.89 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on VTR. Weiss Ratings raised Ventas from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, July 21st. Cantor Fitzgerald raised their price objective on Ventas from $97.00 to $102.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. The Goldman Sachs Group reiterated a “buy” rating and issued a $110.00 price objective on shares of Ventas in a research report on Tuesday, May 19th. Scotiabank boosted their price objective on Ventas from $93.00 to $95.00 and gave the company a “sector perform” rating in a research report on Wednesday, September 2nd. Finally, Wells Fargo & Company upped their target price on Ventas from $96.00 to $104.00 and gave the company an “overweight” rating in a research note on Tuesday, September 1st. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Ventas currently has an average rating of “Moderate Buy” and a consensus price target of $99.00.

Ventas Company Profile

Ventas, Inc is a real estate investment trust (REIT) that owns and manages a diversified portfolio of healthcare and senior living properties. Its real estate platform includes senior housing communities, medical office buildings, life science and innovation centers, and other healthcare-related facilities.

The company generally leases or operates its properties through relationships with healthcare providers, senior living operators, universities, and research institutions. Its properties support services such as independent and assisted living, skilled nursing, outpatient care, physician practices, medical research, and biotechnology development.

Ventas serves major healthcare and life science markets in the United States and Canada.